Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine and Lenvatinib with radiation in locally advanced rectal adenocarcinoma
NCT02935309Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Oct 2016
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lenvatinib in rectal adenocarcinoma, sponsored by Moffitt Cancer Center. Primary endpoint: Maximum Tolerated Dose at 6 months. Started Oct 2016; status: completed.
02
Drugs
lenvatinib
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT02935309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02935309.